Proportion and conditions of use of intranasal take-home naloxone kits: A retrospective study in two French outpatient addiction centers, 2016-2020.

Background: Take-home naloxone (THN) helps to revert the medical consequences of an opioid overdose among people who use drugs (PWUD). In France, an intranasal THN was available from July 2016 to Dec 2020, which was directly dispensed in addiction centers, after a specific education program. However, this intranasal THN was subsequently removed from the market.

[Feedback from two French addiction centers and national survey on the intranasal naloxone (Nalscue) in the prevention of opioid overdoses].

Objective: France has temporarily authorized addictology centers to use a form of intranasal naloxone (Nalscue) to prevent opioid overdoses. The objectives of this work are to present both the characteristics of the patients included in this device in two hospitals centers and the results of the national survey on addiction center's contribution to this new risk reduction tool.

Methods: Patient data are those requested under Nalscue study (inclusion period July 2016 to January 2018).